CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to revolutionize cancer treatment by exploiting the unique DNA-binding properties of oncogenic transcription factors to deliver therapeutic genes specifically to cancer cells. It aims to develop advanced viral vectors and explore their efficacy in treating aggressive pediatric cancers.
Many aggressive cancers, such as pediatric high-risk Ewing sarcoma and alveolar rhabdomyosarcoma, are fueled by and addicted to chimeric oncogenic transcription factors (OTFs).
So far, all attempts to suppress these potent OTFs largely failed, wherefore they are classified as undruggable.This proposal challenges this dogma with a novel strategy to leverage, rather than to suppress, the exquisite neomorphic DNA-binding preferences of OTFs to express therapeutic genes specifically in cancer cells.…
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
